News

Lundbeck Showcases Groundbreaking Data in Neurology Research

Lundbeck Showcases Groundbreaking Data in Neurology Research

Lundbeck's Exciting Presentations at the AAN Annual Meeting

H. Lundbeck A/S (Lundbeck) is set to unveil positive interim results from its ongoing efforts at the upcoming American Academy of Neurology (AAN) Annual Meeting. This includes vital insights into the PACIFIC trial focused on bexicaserin, showcasing Lundbeck's commitment to addressing the complex challenges associated with developmental and epileptic encephalopathies (DEEs).

PACIFIC Trial Findings

The PACIFIC trial is a landmark investigation into bexicaserin, a promising new treatment aimed at combatting seizures in DEEs, which represent one of the most challenging and severe forms of epilepsy. These conditions often lead to drug-resistant seizures, significantly affecting a patient's quality of life. The forthcoming AAN session will highlight six-month results from the open-label extension of the Phase 1b/2a trial, reinforcing the potential of bexicaserin in treating these challenging conditions.

Addressing Unmet Medical Needs

With over 900 genes linked to DEEs, the complexity of these conditions leaves many patients without effective treatment options. Lundbeck's ongoing research demonstrates a growing commitment to fill this gap. According to Johan Luthman, EVP and Head of Research & Development at Lundbeck, the positive data emerging from the PACIFIC trial suggests that bexicaserin may provide meaningful benefits to many individuals affected by DEEs.

Trial Highlights and Results

The open-label extension of the PACIFIC trial has shown a generally favorable safety and tolerability profile for bexicaserin after six months of treatment. Notably, all treatment-naive patients transitioned successfully from a placebo to bexicaserin, confirming its tolerability. The interim analysis reported a striking 57.3% reduction in countable motor seizures and a 61.2% reduction in total seizures during this period. More than half of the newly treated patients noted at least a 50% reduction from baseline, underscoring the potential efficacy of this novel treatment.

Insights on Eptinezumab

In addition to the findings on bexicaserin, Lundbeck will also present compelling analyses and real-world data regarding eptinezumab. This research focuses on clinically meaningful endpoints, including the frequency of good days experienced by patients and sustained treatment response over time.

Transformative Impact on Migraine Treatment

For many, debilitating migraines significantly limit daily activities, and the holistic understanding of their impact on quality of life is crucial. Lundbeck aims to elevate expectations in preventive migraine treatment, ensuring patients receive effective options tailored to their individual needs.

Details of Lundbeck's AAN Presentations

Key presentations at the AAN 2025 will include:

  • Bexicaserin Oral Presentation: Exploring safety, tolerability, and efficacy in participants with DEEs on April 7 during Session S20.
  • Eptinezumab Poster Presentations: Covering long-term maintenance of migraine responses and the patient-reported impacts of migraine treatments.

About Bexicaserin

Bexicaserin (LP352) is an innovative oral treatment that acts as a superagonist on the 5-HT2C receptors and is currently undergoing a global Phase III program. It has been granted Breakthrough Therapy Designation for the treatment of seizures associated with DEEs in patients aged two and older. While promising, it remains an investigational compound that is not yet approved for marketing.

About Eptinezumab

Eptinezumab is a humanized monoclonal antibody developed specifically for intravenous use and targets calcitonin gene-related peptide (CGRP) to prevent migraines. It has shown significant efficacy in reducing the number of migraine days in clinical trials and is currently available in multiple markets globally.

About H. Lundbeck A/S

Lundbeck stands as a dedicated biopharmaceutical leader in brain health, actively working to improve the quality of life for those suffering from neurological and psychiatric disorders. With a workforce of approximately 5,500 and a presence in more than 80 countries, their mission is underscored by a commitment to innovative solutions that address critical health challenges in neurology. Lundbeck is focused on advancing treatments that can genuinely transform the lives of patients.

Frequently Asked Questions

What is the PACIFIC trial?

The PACIFIC trial investigates the efficacy and safety of bexicaserin in treating seizures associated with Developmental and Epileptic Encephalopathies.

When will Lundbeck present its findings?

Lundbeck's findings will be presented during the American Academy of Neurology Annual Meeting.

What is eptinezumab?

Eptinezumab is a monoclonal antibody treatment aimed at preventing migraines by blocking specific proteins associated with migraine attacks.

What are the key results from the trial?

The initial results from the OLE showed significant reductions in both countable motor seizures and total seizures for patients treated with bexicaserin.

How is Lundbeck contributing to neurological health?

Lundbeck focuses on research and development in neuroscience, dedicated to producing innovative treatments for complex neurological conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 120

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 77

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 147

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 121

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 83

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 126

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 92

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 219

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading

Top 5 Most Recently Viewed Articles

Major Analyst Upgrades: Johnson & Johnson a Key Focus Today

Updated Category News Views 167

Exciting Analyst Upgrades in the Stock Market The stock market is constantly evolving, and today's news shining a spotlight on several major companies is particularly noteworthy. Top Wall Street analysts have made significant changes to their outlooks for various stocks, resulting in several upgrades. Let’s take a closer look at these changes and what they might mean...

Continue Reading
Albany International Corp Facing Legal Scrutiny Over Misstatements

Updated Category News Views 317

Albany International Corp Under Investigation Investors of Albany International Corp. are currently facing significant legal concerns that have given rise to an investigation. This inquiry is primarily centered on potential allegations of misleading statements issued by the company, which may have ultimately led to unexpected financial repercussions. As a well-known...

Continue Reading
Toncoin Experiences Notable Decline of Over 4% Today

Updated Category News Views 131

Toncoin Price Analysis for Recent Days Recently, Toncoin experienced a notable decline, with its price dropping by 4.56% in just 24 hours, settling at $5.42. This downturn is quite different from its strong performance last week, during which Toncoin rose by an impressive 5.0%, increasing from $5.16 to the current price. Recent Price Movements and Volatility A closer look...

Continue Reading
AgriFORCE Unveils Innovative Strategy for Digital Infrastructure Growth

Updated Category News Views 209

Revolutionizing the Digital Landscape: AgriFORCE's Strategy AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI), a key player in the digital infrastructure sector, has recently announced an innovative tri-pillar strategy designed to meet the growing global thirst for computational power. As demands for technology continue to rise, this comprehensive framework focuses on Bitcoin...

Continue Reading
Rethinking Infrastructure Finance: Unlocking Trillions

Updated Category News Views 32

Cracking Open the Infrastructure Conundrum If you think America’s infrastructure is crumbling because of a lack of money, you’re only half right. The real hiccup lies in how we’ve rigged the system to access the cash pile. That’s what Anton Steshenko from the University of Maryland’s Smith School is shouting from the rooftops. According to him, it’s not a...

Continue Reading